Advertisement
Canada markets open in 35 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7294
    -0.0003 (-0.04%)
     

  • CRUDE OIL

    82.97
    +0.16 (+0.19%)
     

  • Bitcoin CAD

    86,883.12
    -4,217.04 (-4.63%)
     

  • CMC Crypto 200

    1,359.84
    -22.73 (-1.64%)
     

  • GOLD FUTURES

    2,340.50
    +2.10 (+0.09%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6960
    +0.0440 (+0.95%)
     

  • NASDAQ futures

    17,398.75
    -265.75 (-1.50%)
     

  • VOLATILITY

    16.70
    +0.73 (+4.58%)
     

  • FTSE

    8,081.62
    +41.24 (+0.51%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6820
    +0.0001 (+0.01%)
     
MARKETS LIVE BLOG:

STOCK FUTURES SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

StageZero Announces Fourth Quarter 2019 Results and Year End Investor Call

ACCESSWIRE

TORONTO, ON / ACCESSWIRE / May 13, 2020 / StageZero Life Sciences ("StageZero" or the "Company") (SZLS.TO) today announced that it will release its Fourth Quarter 2019 operational results before markets open on Friday, May 15, 2020. StageZero's Chairman and CEO, James R Howard-Tripp, will host a conference call and online presentation at 8:30 am ET on May 15th to review the operational results and discuss business developments for the period.

Event Date: Friday, May 15, 2020
Time: 8:30 AM EST
Participant: (844) 369-8770 | (862) 298-0840
Replay: (877)-481-4010 | PIN 34859
International Replay: (919)-882-2331
Webcast Link: https://www.webcaster4.com/Webcast/Page/2082/34859
Teleconference Replay Expiration: May 15, 2021 08:30:00 ET

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (nasal swab) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and phlebotomist who can prescribe and draw samples for individuals and groups. As we provide COVID-19 test during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. www.stagezerolifesciences.com

ADVERTISEMENT

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Company Contacts:

James R. Howard-Tripp
Chairman & CEO
jht@stagezerols.com
Tel: 1-855-420-7140 Ext. 1

Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences



View source version on accesswire.com:
https://www.accesswire.com/589682/StageZero-Announces-Fourth-Quarter-2019-Results-and-Year-End-Investor-Call